Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multi-specific drugs for liver cancer...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Hepatocellular carcinoma (HCC) exhibits poor response to chemotherapy due to ineffective drug delivery.
• Exosomes (Exos) are natural nanoscale vesicles capable of efficient intercellular payload delivery.
• Targeting strategies are crucial for enhancing therapeutic efficacy in liver cancer treatment.

Purpose of the Study:

• To develop GalNAc-decorated exosomes for targeted delivery of Paclitaxel (PTX) and miR122 to liver cancer cells.
• To evaluate the efficacy of this multi-specific exosome system in inhibiting HCC growth in vitro and in vivo.
• To assess the potential of exosomes as a drug delivery vehicle for difficult-to-treat cancers.

Main Methods:

• Construction of a 4-way junction (4WJ) RNA nanoparticle to encapsulate PTX and miR122.
• Loading of the RNA-PTX-miR122 complex into exosomes.
• Decoration of exosome surfaces with GalNAc for targeting the asialoglycoprotein receptor (ASGP-R) overexpressed on HCC cells.
• In vitro cancer cell inhibition assays and in vivo mice xenograft studies.

Main Results:

• GalNAc-decorated exosomes selectively bound and delivered their payload into liver cancer cells.
• The multi-specific exosomes demonstrated significant inhibition of HCC growth.
• Mice xenograft studies confirmed efficient liver cancer inhibition following systemic injection of the engineered exosomes.
• Reduced effective drug dosage was observed, indicating high efficiency and low toxicity.

Conclusions:

• GalNAc-decorated exosomes serve as an effective platform for targeted delivery of anticancer therapeutics like PTX and miR122.
• This multi-specific exosome strategy offers a promising approach for treating challenging cancers such as HCC.
• Exosomes represent a viable natural cargo vehicle for enhancing the efficacy and reducing the toxicity of cancer treatments.